Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Another Option in Our KIT of Effective Therapies for Advanced Melanoma

13 Aug 2013

Abstract excerpt

Hodi et al reported the final results of a multicenter phase II trial of imatinib in patients with advanced melanoma harboring mutations or amplification of the KIT proto-oncogene. KIT is a transmembrane receptor tyrosine kinase, normally expressed on melanocytes, that plays a critical role in melanocyte migration, survival, proliferation, and differentiation. Mutations and amplification of KIT have been...

Topics

Join the communities discussing this publication.

Cutaneous Melanoma Detection and Management
Mast cells and histamine
Melanoma and MAPK Pathways

Source

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Identifiers

PMID: 23940226
DOI: 10.1200/jco.2013.50.3144

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 1 Sept 2026.

Community interpretation

Discuss the evidence

Ask a question, add context or challenge an interpretation. Community activity is separate from scientific evidence strength.

0

discussions

0

replies

Citations encouraged

Claims remain attributable.

No discussion yet

Be the first to add a careful, cited interpretation.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Another Option in Our KIT of Effective Therapies for Advanced MelanomaPMID 23940226Read ↗

KIT as a therapeutic target in metastatic melanoma.Semantic proximity Read ↗

Imatinib for melanomas harboring mutationally activated or amplified KIT arising on mucosal, acral, and chronically sun-damaged skin.Semantic proximity Read ↗

Targeting KIT in melanoma: a paradigm of molecular medicine and targeted therapeutics.Semantic proximity Read ↗

Advances in targeted therapy for melanoma.Semantic proximity Read ↗

KIT and Melanoma: Biological Insights and Clinical Implications.Semantic proximity Read ↗

A phase 2 trial of dasatinib in patients with locally advanced or stage IV mucosal, acral, or vulvovaginal melanoma: A trial of the ECOG-ACRIN Cancer Research Group (E2607).Semantic proximity Read ↗

c-Kit inhibitors for unresectable or metastatic mucosal, acral or chronically sun-damaged melanoma: a systematic review and one-arm meta-analysis.Semantic proximity Read ↗

Treatment of acral and mucosal melanoma: Current and emerging targeted therapies.Semantic proximity Read ↗

Phase 2 study of sunitinib in patients with metastatic mucosal or acral melanoma.Semantic proximity Read ↗

Clinical and genomic correlates of imatinib response in melanomas with KIT alterations.Semantic proximity Read ↗

Somatic Activation of KIT in Distinct Subtypes of MelanomaSemantic proximity Read ↗

Imatinib targeting of KIT-mutant oncoprotein in melanoma.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.